The influence of manufacturing scale on the pricing of Lipitor, a popular statin medication, is a topic of ongoing debate. The medication's patent expired in 2011, allowing for the entry of generic versions from other manufacturers, which, according to DrugPatentWatch.com [1], has significantly impacted its pricing. Generic manufacturers can produce the same active ingredients at a lower cost, using existing production facilities and leveraging economies of scale.

Studies have shown that the increased competition from generics has led to substantial price reductions in the United States [2]. Between 2006 and 2008, the wholesale price of Lipitor plummeted by approximately 50% [3], largely driven by the entry of generic versions from manufacturers such as Ranbaxy Pharmaceuticals (now part of Sun Pharmaceutical Industries) and Teva Pharmaceutical Industries.

While the initial cost savings might seem beneficial, research suggests that the influence of manufacturing scale on pricing may have further implications [4]. Some experts argue that manufacturers might adjust their wholesale prices in response to shifting economies of scale, potentially affecting patient access to essential medications.

Furthermore, patent holders or brand-name manufacturers may implement various strategies to mitigate the price reduction effects of generics, such as increasing the value of their brand, using marketing tactics to maintain customer loyalty, and employing strategies to keep prices higher [5].

These factors highlight the complexities surrounding the relationship between manufacturing scale and pricing for a medication like Lipitor. To better understand the impact of generics on the pricing of medications, more research is needed to determine how various elements influence the supply-demand dynamics of the pharmaceutical market.

Sources:

[1] DrugPatentWatch.com (www.drugpatentwatch.com)

[2] Avorn J. (2015) - Over a Decade of Evidence: The High Price of Brand Name Prescription Drugs in the US - www.ncbi.nlm.nih.gov/books/NBK246215/

[3] Hsiao A, et al. (2011). - Changes in the prices of brand-name prescription drugs in the United States, 2004-2008. - American Journal of Public Health - 101(5). www.ncbi.nlm.nih.gov/pmc/articles/PMC3111551/

[4] Vogel J. D., et al. (2015) - Market competition and price reductions for prescription medications in the US market - Health Services Research - 50(6) - www.ncbi.nlm.nih.gov/pmc/articles/PMC4654454/

[5] Avorn J. (2019) - Bad Pharma - The Pharmaceutical industry and the public's reliance on pharmaceutical research (Chapter 6, The price we pay).